Abbott Laboratories
—- Market cap
- $180.03B
- Debt
- —
- Cash
- −$8.52B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $180.03B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
Decision snapshot: ABT stock price near parity vs BDX $103.36 current versus $112.76 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BDX's multiple
Implied fair value · at ABT's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
12 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 71% equity / 29% debt · EV / Revenue 3.05x · EV proxy / EBITDA proxy 13.21x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ABBOTT LABORATORIES · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
BECTON, DICKINSON AND COMPANY · implied price per share
Bear
$55.64
Base
$79.14
Bull
$110.83
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ABT can sustain its superior margins and ROIC while BDX's faster growth does not persist, then a modest long position in ABT makes sense because the valuation discount versus BDX is small and ABT's balance sheet is materially stronger.
On a P/E basis, ABT trades slightly cheaper than BDX at 29.0x versus 30.4x, which supports only a modest relative valuation case. The implied price of $113.04 is just 4.9% above the current price of $107.81, suggesting limited near-term rerating potential from BDX comparison alone.
Supporting Metrics